General Updates

September 7, 2026 BSE Limited National Stock Exchange of India Limited P J Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543904 Symbol: MANKIND Dear Sir/Madam, Sub: Update on voluntary liquidation of Bharat Serums and Vaccines Limited, a wholly owned subsidiary of Mankind Pharma Limited Ref: Regulation 30 and 51 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) This is in continuation to our earlier communication dated August 26, 2026, wherein we had informed about the initiation of preparatory activities for the voluntary liquidation process of Bharat Serums and Vaccines Limited (“BSVL”). In this regard, we wish to inform that the members of BSVL in their Extraordinary General Meeting held today, i.e., September 7, 2026, have accorded their approval for undertaking voluntary liquidation of BSVL (subject to approval of the creditors of BSVL in terms of the provisions of the Insolvency and Bankruptcy Code, 2016 read with the Insolvency and Bankruptcy Board of India (Voluntary Liquidation Process) Regulations, 2017). The detailed disclosure as required pursuant to the applicable provisions of the Listing Regulations and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated January 30, 2026, were already provided by the Company in its intimation dated August 26, 2026. You are requested to kindly take the above information on your records. Thanking you, Yours faithfully, For Mankind Pharma Limited Hitesh Kumar Jain Company Secretary & Compliance Officer